Canadian Clinical Research

Celebrating International Clinical Trials Day on May 20th!

05/19/2023

May 20th celebrates International Clinical Trials Day, as a time to give thanks and support to all the exceptionally hard-working clinical research pros out there! Their work is like putting together a massive puzzle that maps out the terrain of public health and medicine. We set aside May 20th each year to tip our hats…

Read More

Funding from Ontario Institute for Cancer Research to help move research from experiment to impact

08/22/2022

First round of Innovation to Implementation Supplement (I2IS) grants awarded to five promising research projects taking unique approaches to addressing cancer. Excerpt from the Press Release: August 11, 2022, TORONTO – Five Ontario-based research projects will take the next step toward advancing cancer care in the province thanks to funding from the Ontario Institute for…

Read More

Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test

08/17/2022

Excerpt from the Press Release: EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today announced that Health Canada has granted Authorization under Interim Order for the emergency…

Read More

Health Canada Authorizes Moderna’s COVID-19 Vaccine in Young Children (6 Months-5 Years)

07/21/2022

Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults Excerpt from the Press Release: CAMBRIDGE, MA / ACCESSWIRE / July 14, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has approved the use of…

Read More

NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC

04/13/2022

– Patent valid through 2038 – Phase IIb ALS trial expected to commence H1 2022 Excerpt from the Press Release: CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced the Canadian Intellectual Property Office has granted the Company a key patent titled “Compositions…

Read More

Dubai on the Brain: NeuroVigil’s Philip Low Assembles Dream Team to Launch Modern Neurotechnology Industry; Expands Conglomerate in Montreal, Canada

04/01/2022

Senior leaders in science, government, and industry recruited for international “Manhattan Project for the Brain” Excerpt from the Press Release: DUBAI, United Arab Emirates & PALO ALTO, Calif. & MONTREAL–(BUSINESS WIRE)–Neurotechnology Powerhouse NeuroVigil (ranked “Top 10 most innovative companies in health care” by Washington Post and Fast Company) announced at the New Technology & Mental…

Read More

HeartBeam Partners with Triple Ring Technologies to Co-Develop Telehealth Solution Device

03/18/2022

3D Vector ECG Collection Device Slated for FDA 510k Submission in the Fourth Quarter of 2022 Excerpt from the Press Release: SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a professional services agreement (the “Agreement”) with…

Read More

BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma

03/11/2022

Follows U.S. approval for relapsed or refractory marginal zone lymphoma in 2021 Third approved indication for BRUKINSA in Canada, following mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM) Excerpt from the Press Release: MISSISSAUGA, Ontario & CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company…

Read More

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

03/08/2022

Excerpt from the Press Release: SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’s health services agency, allowing the CardiAMP® Heart Failure Trial to…

Read More

Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada

02/04/2022

Dormant Vaccine Manufacturing site currently owned by an affiliate of Liminal BioSciences intended to bring new capabilities to Ocugen’s medicine portfolio of Canadian and U.S. companies COVAXIN™ (BBV152), if approved, to be the first product manufactured in new upgraded facility New facility includes potential for manufacturing for breakthrough gene therapies and serve as R&D hub…

Read More